Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017)
Aim of review. To present data of clinical trials, systematic reviews and metaanalyses which allow to optimize eradication therapy of Helicobacter pylori (H. pylori) infection. Summary. Standard triple therapy including proton pump inhibitor (PPI), clarithromycin and amoxicillin is the firstline tr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2018-08-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/164 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860290360442880 |
|---|---|
| author | V. T. Ivashkin I. V. Mayev T. L. Lapina A. A. Sheptulin A. S. Trukhmanov R. A. Abdulkhakov S. A. Alekseyenko N. N. Dekhnich R. S. Kozlov I. L. Klyaritskaya S. A. Kurilovich M. F. Osipenko V. I. Simanenkov I. B. Khlynov |
| author_facet | V. T. Ivashkin I. V. Mayev T. L. Lapina A. A. Sheptulin A. S. Trukhmanov R. A. Abdulkhakov S. A. Alekseyenko N. N. Dekhnich R. S. Kozlov I. L. Klyaritskaya S. A. Kurilovich M. F. Osipenko V. I. Simanenkov I. B. Khlynov |
| author_sort | V. T. Ivashkin |
| collection | DOAJ |
| description | Aim of review. To present data of clinical trials, systematic reviews and metaanalyses which allow to optimize eradication therapy of Helicobacter pylori (H. pylori) infection. Summary. Standard triple therapy including proton pump inhibitor (PPI), clarithromycin and amoxicillin is the firstline treatment for H. pylori eradication. At prescription of standard triple therapy various measures increasing its efficacy should be utilized. Classical fourcomponent bismuth tripotassium dicitratebased treatment or quadrotherapy without bismuth including PPI, amoxicillin, clarithromycin and metronidazole may be alternative options for the first line eradication therapy. Quadrotherapy with bismuth tripotassium dicitrate is applied as the basic mode of second line therapy at failure of standard triple therapy. Alternative mode of the second line therapy includes PPI, levofloxacin and amoxicillin. Levofloxacinbased triple therapy can be prescribed only by specialist in gastroenterology at strict indications. Third line therapy is personalized according to the choice of the previous treatment modes. The choice of H. pylori eradication therapy in the Russian Federation is based on empirical approach. The rate of clarithromycin resistance of H. pylori strains in Russia does not exceed 15% in the majority of regional studies. There are data indicating absence of significant metronidazole resistance of H. pylori and low level of double clarithromycin and metronidazole resistance. Efficacy of H. pylori eradication therapy may be enhanced by increasing treatment duration to 14 days. Prescription of new generation PPI or increase of PPI dose are targeted to provide the maximum acid suppression, highly important for successful H. pylori infection eradication. Additional prescription of bismuth tripotassium dicitrate, probiotics or rebamipid increases efficacy of antihelicobacter therapy. Significant decrease of adverse events rate at H. pylori eradication treatment is reached at combined prescription of probiotics. Rebamipid may potentiate reparative processes in the stomach mucosa. Conclusion: Methods of H. pylori eradication optimization can be applied for enhancement of both standard triple therapy and other concomitant treatment modes, and the combination of these methods provides best result for the given patient. |
| format | Article |
| id | doaj-art-7499cbf232a14d7bbd4a82b2466c48a3 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2018-08-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-7499cbf232a14d7bbd4a82b2466c48a32025-02-10T16:14:28ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732018-08-0127442110.22416/1382-4376-2017-27-4-4-21164Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017)V. T. Ivashkin0I. V. Mayev1T. L. Lapina2A. A. Sheptulin3A. S. Trukhmanov4R. A. Abdulkhakov5S. A. Alekseyenko6N. N. Dekhnich7R. S. Kozlov8I. L. Klyaritskaya9S. A. Kurilovich10M. F. Osipenko11V. I. Simanenkov12I. B. Khlynov13Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical UniversityFederal state government-financed educational institution of higher education «Yevdokimov Moscow State University of Medicine and Dentistry»Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical UniversityFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical UniversityFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical UniversityFederal state educational government-financed institution of higher education «Kazan State Medical University»Federal state educational government-financed institution of higher education «Far East state medical university»Federal state educational government-financed institution of higher education «Smolensk state medical university»Scientific Research Institute of Antimicrobial Chemotherapy «Smolensk state medical university»Federal State Autonomous Educational Institution of Higher Education «Vernadsky Crimean Federal University»Federal state government-financed scientific institution «Institute of internal diseases and preventive medicine»State educational government-financed institution of higher professional education «Novosibirsk state medical university»State educational government-financed institution of higher professional education «Mechnikov North-Western state medical university»State educational government-financed institution of higher professional education «Ural state medical university»Aim of review. To present data of clinical trials, systematic reviews and metaanalyses which allow to optimize eradication therapy of Helicobacter pylori (H. pylori) infection. Summary. Standard triple therapy including proton pump inhibitor (PPI), clarithromycin and amoxicillin is the firstline treatment for H. pylori eradication. At prescription of standard triple therapy various measures increasing its efficacy should be utilized. Classical fourcomponent bismuth tripotassium dicitratebased treatment or quadrotherapy without bismuth including PPI, amoxicillin, clarithromycin and metronidazole may be alternative options for the first line eradication therapy. Quadrotherapy with bismuth tripotassium dicitrate is applied as the basic mode of second line therapy at failure of standard triple therapy. Alternative mode of the second line therapy includes PPI, levofloxacin and amoxicillin. Levofloxacinbased triple therapy can be prescribed only by specialist in gastroenterology at strict indications. Third line therapy is personalized according to the choice of the previous treatment modes. The choice of H. pylori eradication therapy in the Russian Federation is based on empirical approach. The rate of clarithromycin resistance of H. pylori strains in Russia does not exceed 15% in the majority of regional studies. There are data indicating absence of significant metronidazole resistance of H. pylori and low level of double clarithromycin and metronidazole resistance. Efficacy of H. pylori eradication therapy may be enhanced by increasing treatment duration to 14 days. Prescription of new generation PPI or increase of PPI dose are targeted to provide the maximum acid suppression, highly important for successful H. pylori infection eradication. Additional prescription of bismuth tripotassium dicitrate, probiotics or rebamipid increases efficacy of antihelicobacter therapy. Significant decrease of adverse events rate at H. pylori eradication treatment is reached at combined prescription of probiotics. Rebamipid may potentiate reparative processes in the stomach mucosa. Conclusion: Methods of H. pylori eradication optimization can be applied for enhancement of both standard triple therapy and other concomitant treatment modes, and the combination of these methods provides best result for the given patient.https://www.gastro-j.ru/jour/article/view/164helicobacter pyloriэрадикационная терапия h. pyloriстандартная тройная терапиясочетанная терапияквадротерапияэзомепразолрабепразолвисмута трикалия дицитратпробиотикребамипидприверженность к лечению |
| spellingShingle | V. T. Ivashkin I. V. Mayev T. L. Lapina A. A. Sheptulin A. S. Trukhmanov R. A. Abdulkhakov S. A. Alekseyenko N. N. Dekhnich R. S. Kozlov I. L. Klyaritskaya S. A. Kurilovich M. F. Osipenko V. I. Simanenkov I. B. Khlynov Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017) Российский журнал гастроэнтерологии, гепатологии, колопроктологии helicobacter pylori эрадикационная терапия h. pylori стандартная тройная терапия сочетанная терапия квадротерапия эзомепразол рабепразол висмута трикалия дицитрат пробиотик ребамипид приверженность к лечению |
| title | Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017) |
| title_full | Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017) |
| title_fullStr | Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017) |
| title_full_unstemmed | Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017) |
| title_short | Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017) |
| title_sort | treatment of helicobacter pylori infection mainstream and innovations review of the literature and russian gastroenterological association advisory council resolution may 19 2017 |
| topic | helicobacter pylori эрадикационная терапия h. pylori стандартная тройная терапия сочетанная терапия квадротерапия эзомепразол рабепразол висмута трикалия дицитрат пробиотик ребамипид приверженность к лечению |
| url | https://www.gastro-j.ru/jour/article/view/164 |
| work_keys_str_mv | AT vtivashkin treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 AT ivmayev treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 AT tllapina treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 AT aasheptulin treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 AT astrukhmanov treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 AT raabdulkhakov treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 AT saalekseyenko treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 AT nndekhnich treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 AT rskozlov treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 AT ilklyaritskaya treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 AT sakurilovich treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 AT mfosipenko treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 AT visimanenkov treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 AT ibkhlynov treatmentofhelicobacterpyloriinfectionmainstreamandinnovationsreviewoftheliteratureandrussiangastroenterologicalassociationadvisorycouncilresolutionmay192017 |